相关临床试验
13
5 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2015
进行中（未招募）
5
38.5%
已完成
5
38.5%
终止
3
23.1%
暂无批准数据
- Kexing Biopharm has entered a strategic partnership with IQVIA in August 2025 to accelerate global clinical development and regulatory approval of its innovative drugs and biosimilars, particularly targeting Europe and other regulated international markets. - The collaboration combines Kexing's R&D pipeline in antiviral, antitumor, immunosuppressant, and metabolic disease treatments with IQVIA's global operational infrastructure and regulatory expertise. - IQVIA's Connected Intelligence platform and data-driven insights are expected to enhance trial efficiency and reduce time-to-market for Kexing's therapeutic candidates. - The partnership addresses critical industry challenges including regulatory complexity and market fragmentation, positioning Kexing to capitalize on the growing trend of emerging biopharma companies driving innovation.
- Frazier Healthcare Partners has successfully closed a $1.3 billion venture capital fund specifically targeting early-stage biotechnology companies and startup creation. - The firm was one of the most active biotech investors in 2024, participating in 17 deals and leading nearly one-third of those transactions. - Recent successful exits include Scorpion Therapeutics' $2.5 billion drug sale to Eli Lilly and major acquisitions like Novartis' $3.5 billion purchase of Chinook Therapeutics. - The new fund launch comes amid declining biotech venture funding, which dropped from $7 billion to $4.8 billion in Q2 2025 according to HSBC Innovation Banking.
- Vertex Pharmaceuticals launched JOURNAVX (suzetrigine) in July 2025, marking the first new class of pain medicine in decades and the first non-opioid treatment for moderate-to-severe acute pain approved by the FDA in over 20 years. - The oral NaV1.8 pain signal inhibitor directly targets pain pathways without addiction risks, offering a safer alternative to opioids for acute pain scenarios including post-surgical recovery and injury care. - This breakthrough represents a major advancement in pain management and aligns with public health efforts to reduce opioid use, with the drug being recognized as a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. - The launch adds to Vertex's expanding portfolio beyond cystic fibrosis, including gene-editing therapies like CASGEVY and treatments in development for kidney disease, type 1 diabetes, and rare genetic disorders.
- Biopharma M&A activity totaled $79.4 billion in 2024, representing approximately half of 2023's total value, though deal volume saw a slight increase when excluding four mega-deals from the previous year. - Vertex Pharmaceuticals led the year's largest acquisition with its $4.9 billion purchase of Alpine Immune Sciences, followed by Gilead's $4.3 billion acquisition of CymaBay and Eli Lilly's $3.2 billion purchase of Morphic. - Oncology remained the dominant therapeutic area for dealmaking, accounting for more than a third of all 2024 biopharma transactions by both number and total value, with approximately $90 billion in cancer-focused deals. - Deal activity shifted toward earlier-stage assets and smaller transactions as buyers digested large previous acquisitions and the supply of late-stage and marketed assets diminished.
• Vertex Pharmaceuticals reported a 13% revenue increase in Q1 2024, reaching $2.7 billion, driven by cystic fibrosis (CF) drug sales and the launch of CASGEVY for sickle cell disease and beta-thalassemia. • The company completed regulatory submissions in the U.S. and EU for its vanzacaftor triple therapy for CF patients aged 6 years and older, potentially setting a new standard in CF treatment. • Vertex is advancing suzetrigine (VX-548) for acute and neuropathic pain, with a rolling NDA submission underway and Phase III trials planned for painful diabetic peripheral neuropathy (DPN). • The acquisition of Alpine Immune Sciences is expected to close this quarter, adding povetacicept (pove), a Phase III-ready molecule for IgA nephropathy (IgAN), to Vertex's portfolio.
